Liver Cancer Community Education
NCT04272619 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 67
Last updated 2025-01-08
Summary
This study proposes to bridge the gap between evidence and action and combat rising liver cancer rates attributed to Hepatitis B and C infection in Philadelphia by identifying neighborhoods with higher than expected rates of liver cancer and related risk factors and administering an educational intervention about liver cancer and neighborhood health in those communities, working with existing community partners at Fox Chase Cancer Center.
Conditions
Interventions
- BEHAVIORAL
-
LIVE-R Life Education
A health educator will present participants with a 30-minute PowerPoint presentation containing educational information about liver cancer risk, screening, prevention, symptoms, and treatments, as well as introduce the concept of neighborhood health (e.g., rates of liver cancer and related risk factors in a census tract and how that might influence individual cancer risk).
Sponsors & Collaborators
-
Pennsylvania Department of Health
collaborator OTHER_GOV -
Fox Chase Cancer Center
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-02-11
- Primary Completion
- 2023-04-06
- Completion
- 2023-04-06
Countries
- United States
Study Locations
More Related Trials
-
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases
NCT00510627 ·Status: WITHDRAWN ·Phase: PHASE4
-
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
NCT00055692 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study Protocol: LIVER-R
NCT06252753 ·Status: RECRUITING
-
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
NCT01356628 ·Status: COMPLETED ·Phase: PHASE2
-
Blood Sample Collection for Experimental Blood Test to Track Liver Cancer
NCT04720430 ·Status: COMPLETED
-
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
NCT05822752 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
NCT00867321 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery
NCT00242502 ·Status: COMPLETED ·Phase: PHASE2
-
Circulating Tumor Cells and Tumor DNA in HCC and NET
NCT02973204 ·Status: COMPLETED
-
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
NCT02513199 ·Status: COMPLETED ·Phase: PHASE2
-
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
NCT03838796 ·Status: UNKNOWN ·Phase: NA
-
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
NCT00813293 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection
NCT02650427 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
NCT00913757 ·Status: COMPLETED
-
Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma
NCT04479527 ·Status: UNKNOWN ·Phase: PHASE2
-
STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention
NCT03706742 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses
NCT05897138 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
NCT04145141 ·Status: ACTIVE_NOT_RECRUITING
-
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
NCT00287222 ·Status: COMPLETED ·Phase: PHASE2
-
Liver Cancer Prognosis Investigation Study
NCT06623734 ·Status: NOT_YET_RECRUITING
-
Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma
NCT03748927 ·Status: WITHDRAWN
-
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
NCT07227012 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Bevacizumab in Advanced Hepatocellular Carcinoma
NCT00162669 ·Status: UNKNOWN ·Phase: PHASE2
-
A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions
NCT06864195 ·Status: RECRUITING
-
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
NCT05194293 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2